Related Experiment Video
Updated: May 30, 2026
09:15
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
[Pleiotropic effects of statins in systemic sclerosis]
Terapevticheskii Arkhiv
|July 26, 2011
Summary
Atorvastatin demonstrated significant anti-inflammatory and angioprotective effects in systemic sclerosis (SS) patients by reducing key inflammatory markers and improving vascular health over 12 months.
Area of Science:
- Rheumatology
- Cardiology
- Immunology
Background:
- Systemic sclerosis (SS) is associated with significant inflammation and vascular damage.
- Elevated levels of inflammatory markers like hs-CRP, IL-6, and adhesion molecules are observed in SS patients.
- Understanding the angioprotective potential of therapeutic agents is crucial for managing SS complications.
Purpose of the Study:
- To evaluate the anti-inflammatory and angioprotective properties of atorvastatin in patients with systemic sclerosis (SS).
- To assess the impact of atorvastatin on specific inflammatory and vascular markers in SS.
Main Methods:
- A 12-month randomized controlled trial involving 50 SS patients.
- Study group (n=30) received standard therapy plus atorvastatin (10-40 mg/day); control group (n=20) received standard therapy alone.
- Enzyme immunoassay was used to measure hs-CRP, IL-6, VCAM-1, E-selectin, WF antigen, VEGF-A, and VEGF-R2 before and after treatment.
Main Results:
- Atorvastatin treatment significantly reduced levels of hs-CRP, IL-6, WF antigen, E-selectin, VEGF-A, and VEGF-R2 in SS patients.
- The number of patients with elevated IL-6, WF antigen, and VEGF-R2 decreased in the atorvastatin group.
- No significant changes in these markers were observed in the control group.
Conclusions:
- Atorvastatin exhibits significant anti-inflammatory effects in SS patients.
- Atorvastatin demonstrates angioprotective properties by improving vascular health markers in SS.
- These findings suggest atorvastatin as a potential therapeutic agent for managing vascular complications in systemic sclerosis.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:20The JAK-STAT Signaling Pathway
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
01:33Pleiotropy
Pleiotropy is the phenomenon in which a single gene impacts multiple, seemingly unrelated phenotypic traits. For example, defects in the SOX10 gene cause Waardenburg Syndrome Type 4, or WS4, which can cause defects in pigmentation, hearing impairments, and an absence of intestinal contractions necessary for elimination. This diversity of phenotypes results from the expression pattern of SOX10 in early embryonic and fetal development. SOX10 is found in neural crest cells that form melanocytes,...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...